Hologic, Inc. (HOLX)
US — Healthcare Sector
Automate Your Wheel Strategy on HOLX
With Tiblio's Option Bot, you can configure your own wheel strategy including HOLX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HOLX
- Rev/Share 17.8338
- Book/Share 20.4572
- PB 3.1827
- Debt/Equity 0.548
- CurrentRatio 3.2421
- ROIC 0.0769
- MktCap 14509437950.0
- FreeCF/Share 4.6055
- PFCF 13.9541
- PE 26.4059
- Debt/Assets 0.2962
- DivYield 0
- ROE 0.1144
- Rating
- Score
- Recommendation
- P/E Score
- DCF Score
- P/B Score
- D/E Score
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Reiterated | HOLX | Needham | -- | Hold | -- | -- | May 27, 2025 |
| Downgrade | HOLX | Argus | Buy | Hold | -- | -- | March 3, 2025 |
| Downgrade | HOLX | Leerink Partners | Outperform | Market Perform | $80 | $75 | Feb. 6, 2025 |
| Downgrade | HOLX | Needham | Buy | Hold | -- | -- | Feb. 3, 2025 |
| Initiation | HOLX | Wolfe Research | -- | Peer Perform | -- | -- | Dec. 13, 2024 |
| Reiterated | HOLX | Needham | -- | Buy | -- | $90 | Dec. 10, 2024 |
| Initiation | HOLX | Jefferies | -- | Hold | -- | $85 | Dec. 10, 2024 |
| Downgrade | HOLX | Citigroup | Buy | Neutral | $95 | $85 | Oct. 1, 2024 |
News
Here's Why You Should Retain HOLX Stock in Your Portfolio Now
HOLX
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Hologic's strength in the molecular diagnostics wing instills optimism among investors. Yet, a dull macroeconomic environment raises concerns.
Read More
About Hologic, Inc. (HOLX)
- IPO Date 1990-03-01
- Website https://www.hologic.com
- Industry Medical - Instruments & Supplies
- CEO Stephen P. MacMillan
- Employees 7063
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.